September 23, 2022
Public Health/Prevention
  • The American Association for Cancer Research (AACR) predicts the U.S. will see an increased incidence of late-stage cancer in the next year. The increase is attributed to a “very significant decline” in early detection, screening, and overall attention to patient health that occurred during the COVID-19 pandemic. The threat could offset the steady progress the U.S. has made in reducing cancer deaths. Between 1991 and 2019, American cancer deaths declined by 32 percent, with a 2.3 percent drop yearly from 2016 to 2019. The FDA also approved eight new “groundbreaking” anticancer therapeutics and two new diagnostic imaging agents between in a one-year period (August 1, 2021 to July 31, 2022). (Report here; Article here)